Tirzepatide® providers &
prescriptions in El Centro, CA
Verified Tirzepatide providers in El Centro, CA. Checked against the NPI registry, never ranked by who pays us.[7]
Find a Tirzepatide provider in California.
Every entry is checked against the federal NPI registry. We do not accept payment for placement.
How to get Tirzepatide in El Centro.
23 GLP-1 prescribers and 5 local resource types are on record for El Centro, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.
Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]
In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]
Community health · CDC
Weight & metabolic health in El Centro
El Centro, California has a population of 44,322 people. The adult obesity rate in El Centro is an age-adjusted estimate of 35.2%, 6.1 percentage points above the California state rate of 29.1%. Diagnosed diabetes reaches 14.5% of adults in El Centro. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 35.4% of adults in El Centro.
- of El Centro adults have obesity
- 35.2%
- diagnosed diabetes
- 14.5%
- no regular physical activity
- 35.4%
Age-adjusted estimates for El Centro, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in El Centro.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near El Centro, CA, ordered as the registry lists them, never by who pays us.
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
1507 W Barbara Worth Dr Apt 42
200 W Arbor Dr
Gyms near you
A gym gives you the regular movement that keeps muscle while the weight comes off.
What the trials actually showed.
We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.
Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]